

Supporting Information

Copper-Catalyzed C–N Bond Formation with Imidazo[1,2-*a*]pyridines

Kai Sun,* Shiqiang Mu, Zhenhua Liu, Ranran Feng, Yali Li, Kui Pang, Bing Zhang

*College of Chemistry and Chemical Engineering, Anyang Normal University, Anyang 455000, P.

R. China. E-mail: sunk468@nenu.edu.cn

Table of Contents

I. General remarks	2
II. General procedure for the preparation of 3.....	2
III. Analytical data of products obtained in this study.....	2-7
IV. ¹H NMR and ¹³C NMR spectra copies of compounds 3.....	8-26

I. General Remarks:

All reagents were purchased from commercial sources and used without further purification. ^1H NMR and ^{13}C NMR spectra were recorded on a Bruker Ascend™ 400 spectrometer in deuterated solvents containing TMS as an internal reference standard. High-resolution mass spectrometry (HRMS) analyses were conducted on a Waters LCT Premier/XE. IR spectra (KBr) were recorded on a Magna-560 FTIR spectrophotometer in the range of 400–4000 cm^{-1} . Melting points were measured on a melting point apparatus equipped with a thermometer and were uncorrected. All the reactions were monitored by thin-layer chromatography (TLC) using GF254 silica gel-coated TLC plates. Purification by flash column chromatography was performed over SiO_2 (silica gel 200–300 mesh).

II. General procedure for the preparation of **3** (**3a** as an example):

2-Phenylimidazo[1,2-*a*]pyridine **1a** (58.2 mg, 0.3 mmol), saccharin **2** (54.9 mg, 0.3 mmol), $\text{Cu}(\text{OAc})_2$ (5.4 mg, 0.03 mmol), Selectfluor (212.4 mg, 0.6 mmol) and Na_2CO_3 (74.4 mg, 0.6 mmol) mixed in 3 mL DCE. The mixture was stirred at 120 °C for 12 h in a Schlenk tube. The reaction was monitored by TLC before being quenched with water (10 mL) and extracted with dichloromethane (5×3 mL). The extracted organics were dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by flash silica gel column chromatography using ethyl acetate/petroleum ether (1:5) as an eluent to give compound **3a** as a white solid (95.6 mg, 83%).

III. Analytical data of products obtained in this study

2-(2-phenylimidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3a**)**. White solid, mp 208-209 °C; ^1H NMR (400 MHz; CDCl_3): δ = 6.87 (t, J = 6.4, 1H), 7.32-7.38 (m, 4H), 7.71 (d, J = 9.2, 1H), 7.91-7.97 (m, 7H). ^{13}C NMR (100 MHz; CDCl_3): δ = 103.7, 113.3, 118.1, 121.7, 123.2, 126.2, 126.3, 127.5, 128.6, 128.8, 132.1, 134.8, 135.9, 138.0, 145.2, 146.4, 158.1. HRMS (ESI-TOF) Calcd for $\text{C}_{20}\text{H}_{14}\text{N}_3\text{O}_3\text{S}$, $[\text{M}+\text{H}]^+$ 376.0574; Found 376.0578. IR (KBr, cm^{-1}): 3032, 1747, 1355,

1185, 669.

2-(2-(*m*-tolyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3b). White solid, mp 116-117 °C; ¹H NMR (400 MHz; CDCl₃): δ = 2.34 (s, 3H), 6.93 (t, *J* = 6.8, 1H), 7.16 (d, *J* = 6.8, 1H), 7.22 (d, *J* = 7.6, 1H), 7.40 (t, *J* = 8.0, 1H), 7.65 (t, *J* = 7.6, 1H), 7.87-7.96 (m, 3H), 8.01-8.06 (m, 3H), 8.12 (d, *J* = 6.4, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 21.4, 113.6, 117.9, 121.7, 123.3, 124.4, 126.2, 127.3, 128.5, 128.7, 129.9, 131.2, 133.9, 134.8, 135.9, 138.1, 138.4, 144.9, 146.2, 158.1. HRMS (ESI-TOF) Calcd for C₂₁H₁₆N₃O₃S, [M+H]⁺ 390.0913; Found 390.0906. IR (KBr, cm⁻¹): 3046, 1766, 1345, 1130, 733.

2-(2-(*p*-tolyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3c). White solid, mp 223-224 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.86 (t, *J* = 6.4, 1H), 7.18 (d, *J* = 8.0, 2H), 7.34 (t, *J* = 7.2, 1H), 7.71 (d, *J* = 9.2, 1H), 7.83 (d, *J* = 8.0, 2H), 7.95-8.10 (m, 4H), 8.20 (d, *J* = 7.2, 1H). ¹³C NMR (100 MHz; CDCl₃): δ = 21.3, 103.3, 113.2, 118.1, 121.7, 123.2, 126.2, 126.3, 126.7, 127.3, 129.2, 129.4, 134.8, 135.8, 138.1, 138.8, 145.2, 146.5, 158.1. HRMS (ESI-TOF) Calcd for C₂₁H₁₆N₃O₃S, [M+H]⁺ 390.0913; Found 390.0908. IR (KBr, cm⁻¹): 3039, 2855, 1758, 1353, 1183, 732.

2-(2-(4-cyclohexylphenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3d). White solid, mp 236-237 °C; ¹H NMR (400 MHz; CDCl₃): δ = 1.34-1.43 (m, 4H), 1.71-1.85 (m, 6H), 2.48 (t, *J* = 7.6, 1H), 6.85 (t, *J* = 6.8, 1H), 7.20-7.35 (m, 3H), 7.71 (d, *J* = 8.8, 1H), 7.88-8.20 (m, 7H). ¹³C NMR (100 MHz; CDCl₃): δ = 26.1, 26.8, 34.2, 44.3, 113.2, 118.0, 121.7, 123.2, 126.2, 126.7, 126.7, 127.3, 129.4, 134.8, 135.8, 138.1, 145.2, 146.4, 148.8, 158.1. HRMS (ESI-TOF) Calcd for C₂₆H₁₄N₃O₃S, [M+H]⁺ 458.1538; Found 458.1532. IR (KBr, cm⁻¹): 3079, 1746, 1386, 1184, 591.

2-(2-(4-methoxyphenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3e). White solid, mp 221-222 °C; ¹H NMR (400 MHz; CDCl₃): δ = 3.80

(s, 3H), 6.89 (q, $J = 7.2$, 3H), 7.34 (q, $J = 6.8$, 1H), 7.05 (d, $J = 8.8$, 1H), 7.89-7.97 (m, 7H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 55.1, 113.1, 114.1, 118.0, 121.7, 123.1, 124.6, 126.2, 126.4, 126.6, 128.8, 134.8, 135.8, 138.1, 145.2, 146.3, 158.1, 160.1$. HRMS (ESI-TOF) Calcd for $\text{C}_{21}\text{H}_{16}\text{N}_3\text{O}_4\text{S}$, $[\text{M}+\text{H}]^+$ 406.0863; Found 406.0865. IR (KBr, cm^{-1}): 3093, 1756, 1337, 733.

2-(2-(3,4-dimethylphenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3f). White solid, mp 114-115 °C; ^1H NMR (400 MHz; CDCl_3): $\delta = 2.24$ - 2.26 (d, 6H), 6.89 (d, $J = 6.8$, 1H), 7.10 (d, $J = 7.6$, 1H), 7.34 (t, $J = 8.0$, 1H), 7.58 (d, $J = 8.0$, 1H), 7.72 (d, $J = 8.8$, 1H), 7.82 (s, 1H), 7.97-8.05 (m, 4H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 19.6, 19.7, 113.2, 118.0, 121.7, 123.2, 124.4, 126.2, 126.4, 126.6, 128.9, 129.5, 129.8, 134.8, 135.8, 136.9, 137.5, 138.1, 145.2, 146.6, 158.1$. HRMS (ESI-TOF) Calcd for $\text{C}_{22}\text{H}_{18}\text{N}_3\text{O}_3\text{S}$, $[\text{M}+\text{H}]^+$ 404.1065; Found 404.1069. IR (KBr, cm^{-1}): 3092, 1749, 1495, 1343, 582.

2-(2-(2-chlorophenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3g). White solid, mp 214-216 °C; ^1H NMR (400 MHz; CDCl_3): $\delta = 6.91$ (t, $J = 6.8$, 1H), 7.29-7.45 (m, 4H), 7.63 (d, $J = 6.8$, 1H), 7.74 (d, $J = 9.2$, 1H), 7.90-8.02 (m, 5H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 106.0, 113.6, 118.5, 121.6, 123.1, 126.0, 126.3, 126.4, 126.8, 130.0, 131.5, 132.1, 133.9, 134.7, 135.6, 137.9, 144.6, 145.0, 157.9$. HRMS (ESI-TOF) Calcd for $\text{C}_{20}\text{H}_{13}\text{ClN}_3\text{O}_3\text{S}$, $[\text{M}+\text{H}]^+$ 410.0367; Found 410.0374. IR (KBr, cm^{-1}): 3049, 1747, 1339, 581.

2-(2-(3-chlorophenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3h). White solid, mp 218-219 °C; ^1H NMR (400 MHz; CDCl_3): $\delta = 6.88$ (d, $J = 6.8$, 1H), 7.29-7.37 (m, 3H), 7.71 (d, $J = 9.2$, 1H), 7.79 (d, $J = 5.2$, 1H), 7.92-7.98 (m, 6H). ^{13}C NMR (100 MHz; CDCl_3): $\delta = 113.6, 118.2, 121.8, 123.3, 125.4, 126.3, 127.1, 127.9, 128.9, 129.8, 130.8, 133.8, 134.6, 134.9, 136.0, 145.2, 158.1, 167.6$. HRMS (ESI-TOF) Calcd for $\text{C}_{20}\text{H}_{13}\text{ClN}_3\text{O}_3\text{S}$, $[\text{M}+\text{H}]^+$ 410.0367; Found 410.0371. IR (KBr, cm^{-1}): 3091, 1742, 1349, 1185, 571.

2-(2-(4-fluorophenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one

1,1-dioxide (3i). White solid, mp 172-173 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.88 (t, *J* = 6.8, 1H), 7.07 (t, *J* = 8.4, 2H), 7.37 (t, *J* = 8.0, 1H), 7.74 (d, *J* = 8.8, 1H), 7.91-7.99 (m, 7H). ¹³C NMR (100 MHz; CDCl₃): δ = 104.1, 113.6, 118.2, 121.8, 123.3, 125.3, 126.3, 127.8, 128.8, 128.9, 129.9, 130.9, 132.3, 133.8, 134.6, 135.0, 136.0 (d, *J* = 190 Hz), 137.9, 144.9, 145.2, 158.1, 167.7. HRMS (ESI-TOF) Calcd for C₂₀H₁₃FN₃O₃S, [M+H]⁺ 394.0664; Found 394.0669. IR (KBr, cm⁻¹): 3033, 1741, 1186, 731, 501.

2-(2-(4-bromophenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one

1,1-dioxide (3j). White solid, mp 226-227 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.89 (t, *J* = 6.8, 1H), 7.35 (d, *J* = 7.6, 1H), 7.39 (t, *J* = 7.2, 2H), 7.50 (d, *J* = 8.4, 1H), 7.81 (d, *J* = 8.4, 2H), 7.97-8.09 (m, 5H). ¹³C NMR (100 MHz; CDCl₃): δ = 113.5, 118.2, 121.8, 123.3, 126.2, 126.3, 127.0, 129.0, 131.0, 131.8, 134.9, 136.0, 138.0, 145.3, 158.0. HRMS (ESI-TOF) Calcd for C₂₀H₁₃BrN₃O₃S, [M+H]⁺ 453.9864; Found 453.9861. IR (KBr, cm⁻¹): 3091, 1748, 1341, 1011, 510.

2-(2-(4-(trifluoromethyl)phenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-

3(2*H*)-one 1,1-dioxide (3k). White solid, mp 223-224 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.90 (t, *J* = 6.8, 1H), 7.36 (d, *J* = 7.6, 1H), 7.73 (d, *J* = 8.0, 2H), 7.96-8.08 (m, 8H). ¹³C NMR (100 MHz; CDCl₃): δ = 104.5, 113.7, 118.3, 121.8, 122.7, 125.4, 125.5 (q, *J*_{C-F} = 12 Hz), 125.6, 126.1, 126.3, 127.2, 127.7, 130.4, 130.7, 135.0, 135.6, 136.0, 138.0, 144.4, 145.4, 158.0. HRMS (ESI-TOF) Calcd for C₂₁H₁₃F₃N₃O₃S, [M+H]⁺ 444.0633; Found 444.0636. IR (KBr, cm⁻¹): 3037, 1760, 1321, 1068, 772.

2-(2-(2,3,4-trichlorophenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one

1,1-dioxide (3l). White solid, mp 224-225 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.96 (t, *J* = 6.8, 1H), 7.41 (t, *J* = 9.6, 2H), 7.48 (d, *J* = 8.4, 1H), 7.75 (t, *J* = 8.4, 1H), 7.75-7.97 (m, 4H). ¹³C NMR (100 MHz; CDCl₃): δ = 106.1, 113.9, 118.6, 121.7, 123.2, 126.2, 127.1, 127.9, 128.8, 130.1, 132.0, 134.3, 134.7, 134.8, 135.8, 137.8, 143.7, 145.1, 157.8. HRMS (ESI-TOF) Calcd for C₂₀H₁₁Cl₃N₃O₃S, [M+H]⁺ 477.9586;

Found 477.9594. IR (KBr, cm⁻¹): 3083, 1740, 1339, 749, 502.

2-(2-(3,5-bis(trifluoromethyl)phenyl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3m). White solid, mp 198-199 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.97 (d, *J* = 6.8, 1H), 7.43 (s, 1H), 7.77 (d, *J* = 9.2, 2H), 8.00-8.16 (m, 5H), 8.23 (d, *J* = 13.2, 2H). ¹³C NMR (100 MHz; CDCl₃): δ = 105.0, 114.1, 118.4, 121.8, 122.3, 123.4, 124.5, 125.9, 126.3, 127.5, 127.6, 131.4 (q, *J*_{C-F} = 34 Hz), 131.8, 132.1, 132.4, 134.2, 135.1, 136.3, 137.9, 143.1, 145.4, 158.1. HRMS (ESI-TOF) Calcd for C₂₂H₁₂F₆N₃O₃S, [M+H]⁺ 512.0504; Found 512.0509. IR (KBr, cm⁻¹): 3046, 1757, 1278, 738, 585.

2-(2-(thiophen-2-yl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3n). White solid, mp 231-233 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.88 (t, *J* = 6.8, 1H), 7.32 (dd, *J*₁ = 3.2, *J*₂ = 4.8, 2H), 7.60 (d, *J* = 4.2, 1H), 7.69 (d, *J* = 9.2, 1H), 7.92-8.08 (m, 6H). ¹³C NMR (100 MHz; CDCl₃): δ = 103.0, 113.3, 117.9, 121.8, 123.2, 126.0, 126.3, 126.6, 126.9, 133.1, 134.9, 136.0, 138.0, 142.6, 145.3, 157.9. HRMS (ESI-TOF) Calcd for C₁₈H₁₂N₃O₃S₂, [M+H]⁺ 382.0320; Found 382.0316. IR (KBr, cm⁻¹): 3030, 1745, 1341, 1058, 585.

2-(2-(5-chlorothiophen-2-yl)imidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3o). White solid, mp 241-242 °C; ¹H NMR (400 MHz; CDCl₃): δ = 6.82 (d, *J* = 3.6, 1H), 6.88 (t, *J* = 6.8, 1H), 7.34 (t, *J* = 9.2, 2H), 7.67 (d, *J* = 9.2, 1H), 7.98-8.08 (m, 5H). ¹³C NMR (100 MHz; CDCl₃): δ = 103.0, 113.3, 117.9, 121.8, 123.2, 126.0, 126.3, 126.6, 126.9, 133.1, 134.9, 136.0, 138.0, 142.6, 145.3, 157.9. HRMS (ESI-TOF) Calcd for C₁₈H₁₁ClN₃O₃S₂, [M+H]⁺ 415.9931; Found 415.9938. IR (KBr, cm⁻¹): 3077, 1741, 1448, 735, 496.

2-(6-fluoro-2-phenylimidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide (3p). White solid, mp 220-221 °C; ¹H NMR (400 MHz; CDCl₃): δ = 7.26 (d, *J* = 7.6, 1H), 7.36 (d, *J* = 7.2, 3H), 7.68 (q, *J* = 4.8, 1H), 7.92-8.00 (m, 7H). ¹³C NMR (100 MHz; CDCl₃): δ = 110.3, 110.7, 118.7, 118.8, 119.0, 121.8, 126.2, 126.3, 127.4,

128.6, 129.0, 131.8, 134.9, 136.0, 138.0, 142.8, 147.6, 154.9 (d, $J = 238$ Hz), 157.9. HRMS (ESI-TOF) Calcd for $C_{20}H_{13}FN_3O_3S$, $[M+H]^+$ 394.0664; Found 394.0668. IR (KBr, cm^{-1}): 3092, 1746, 1339, 1185, 1177, 503.

2-(7-methyl-2-phenylimidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one

1,1-dioxide (3q). White solid, mp 242-243 °C; 1H NMR (400 MHz; $CDCl_3$): $\delta = 2.45$ (s, 3H), 6.71 (d, $J = 6.8$, 1H), 7.33 (q, $J = 7.6$, 3H), 7.49 (s, 1H), 7.92-7.97 (m, 6H), 8.01 (d, $J = 7.2$, 1H). ^{13}C NMR (100 MHz; $CDCl_3$): $\delta = 21.4$, 115.9, 116.6, 121.7, 122.4, 126.3, 127.4, 128.5, 128.7, 132.2, 134.8, 135.8, 138.0, 145.6, 158.2. HRMS (ESI-TOF) Calcd for $C_{21}H_{16}N_3O_3S$, $[M+H]^+$ 390.0913; Found 390.0906. IR (KBr, cm^{-1}): 3087, 1758, 1339, 1185, 586.

2-(8-methyl-2-phenylimidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one



1,1-dioxide (3r). White solid, mp 52-53 °C; 1H NMR (400 MHz; $CDCl_3$): $\delta = 2.72$ (s, 3H), 6.80 (s, 1H), 7.13 (q, $J = 7.2$, 1H), 7.35 (q, $J = 7.6$, 3H), 7.94-8.04 (m, 6H), 8.19 (d, $J = 7.6$, 1H). ^{13}C NMR (100 MHz; $CDCl_3$): $\delta = 22.6$, 103.9, 113.3, 121.0, 121.7, 125.4, 126.2, 126.4, 127.7, 128.2, 128.5, 128.6, 132.3, 134.8, 135.8, 138.1, 145.5, 146.1, 158.2. HRMS (ESI-TOF) Calcd for $C_{21}H_{16}N_3O_3S$, $[M+H]^+$ 390.0913; Found 390.0909. IR (KBr, cm^{-1}): 3055, 1741, 1342, 743, 582.

2-(7-chloroimidazo[1,2-*a*]pyridin-3-yl)benzo[*d*]isothiazol-3(2*H*)-one 1,1-dioxide


(3t). White solid, mp 164-165 °C; 1H NMR (400 MHz; $CDCl_3$): $\delta = 6.89$ (dd, $J_1 = 1.6$, $J_2 = 7.6$, 1H), 7.72 (d, $J = 1.2$, 1H), 7.89 (s, 1H), 7.96-7.98 (s, 4H), 8.02 (d, $J = 7.26$, 1H). ^{13}C NMR (100 MHz; $CDCl_3$): $\delta = 115.3$, 117.5, 121.8, 123.3, 126.1, 126.3, 133.2, 134.9, 135.5, 135.9, 137.9, 158.0. HRMS (ESI-TOF) Calcd for $C_{14}H_9ClN_3O_3S$, $[M+H]^+$ 334.0057; Found 334.0053. IR (KBr, cm^{-1}): 3078, 17504, 13446, 1175, 578.


V. ^1H NMR and ^{13}C NMR spectra copies of compounds 3

Compound 3a





Compound **3b**









Compound **3c**





Compound **3d**





Compound **3e**





Compound **3f**





Compound **3g**





Compound **3h**





Compound **3i**





Compound **3j**





Compound **3k**




Compound **31**





Compound **3m**





Compound **3n**





Compound **3o**





Compound **3p**



Compound **3q**



Compound **3r**



Compound **3t**

